Raymond James Upgrades Liquidia to Strong Buy on Surging Yutrepia Demand and Settlement
Analyst Ryan Deschner lifted Liquidia’s rating and price target to $77, citing robust PAH demand, rising shipments, and resolved litigation with United Therapeutics.